Our Vision In Action
Our platform enables discovery of high-quality, novel molecules more rapidly, at lower cost
Our world-class drug discovery and development team is leveraging our computational platform and massive computing power to advance our proprietary programs both independently and in collaboration with leading biotech and pharmaceutical companies.
|
SGR-1505 (MALT1)Relapsed /
Resistant Non-Hodgkin's Lymphoma |
|
Schrödinger |
|---|---|---|
|
SGR-2921 (CDC7)Hematological Cancers and Solid Tumors |
|
Schrödinger |
|
SGR-3515 (Wee1)Gynecological Cancers and other Solid Tumors |
|
Schrödinger |
| LRRK2Neurology |
|
Schrödinger |
| Multiple Oncology Programs |
|
Schrödinger |
| Multiple Immunology Programs |
|
Schrödinger |
|
SOS1 / KRASKRAS-Driven Cancers |
|
Schrodinger and Bristol Myers Squibb |
| UndisclosedOncology |
|
Schrodinger and Bristol Myers Squibb |
| UndisclosedOncology |
|
Schrodinger and Bristol Myers Squibb |
| UndisclosedImmunology |
|
Schrodinger and Bristol Myers Squibb |
| UndisclosedNeurology |
|
Schrodinger and Bristol Myers Squibb |
| Protein DegradersOncology,
Immunology and Neurology |
|
Schrodinger and Bristol Myers Squibb |
| UndisclosedOncology |
|
Schrodinger and Takeda |
| Undisclosed |
|
Schrodinger and Lilly |
|
TIBSOVO*
|
|
|---|---|
|
IDHIFA*
|
|
|
Oncology
|
|
|
Oncology
|
|
|
Antifungal
|
|
|
Oncology
|
|
|
Inflammatory Bowel Diseases
|
|
|
Fibrosis
|
|
|
GI Indications
|
|
|
Solid Tumors
|
|
|
Undisclosed
|
|
|
Metabolic Diseases**
|
|
|
Autoimmune and Inflammatory Diseases
|
|
|
Immuno-oncology
|
|
|
Autoimmune Disease and Cancer
|
|
|
Immuno-oncology
|
|
|
Undisclosed Targets
|
|
|
CNS
|
|
|
Autoimmune Disease
|
|
|
Oncology
|
|
|
Pulmonary Arterial Hypertension
|
|
|
Type 2 Diabetes / Obesity
|
|
|
Idiopathic Pulmonary Fibrosis
|
|
|
Oncology
|
|
|
Undisclosed
|
|
* Acquired by Servier
** Acquired by Gilead